ReoPro abciximab GPIIb/IIIa platelet inhibitor: Phase III data; marketed to reduce acute ischemic cardiac complications in patients undergoing percutaneous coro

CNTO presented six-month follow-up data showing a sustained long-term benefit in its 2,399-patient EPISTENT Phase III trial comparing ReoPro plus stents or

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE